AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A method of increasing the sensitivity of cancer cells or a tumour to a chemotherapeutic agent by contacting said cells or tumour with an isoflavonoid compound of formula 12~~(VI) or (VII)~~:



12



(VI)



(VII)

~~wherein~~

~~R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or~~

~~R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



~~; or~~

~~R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



~~;~~

~~W is R_1;~~

~~R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,~~

~~R_4 is hydrogen, alkyl or aryl, or~~

~~R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,~~

~~R_6 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$;~~

~~R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} where each R_{13} is independently hydrogen, alkyl or aryl,~~

~~R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,~~

~~the drawing "—" represents either a single bond or a double bond,~~

~~T is independently hydrogen, alkyl or aryl,~~

~~R_{14}, and R_{15} are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or R_{14} and R_{15} are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,~~

~~and pharmaceutically acceptable salts thereof, and,~~

wherein the cancer is ovarian, pancreatic or prostate cancer, and

the chemotherapeutic agent is ~~platinum-based or anti-mitotic agent~~cisplatin, carboplatin, paclitaxel, gemcitabine or doxorubicin.

2. (previously presented): A method of claim 1, wherein prior to the contacting, the cancer cells or tumour were/was not sensitive to the chemotherapeutic agent.

3. (currently amended): A method of claim 1, wherein the compound of formula 12~~(VI) or (VII)~~ is administered to a subject in need of such treatment.

4. (currently amended): A combination therapy for the treatment or prophylaxis of ~~cell proliferation,~~ cancer ~~or a disease associated with oxidant stress~~ comprising administering to a subject a therapeutically effective amount of a compound of formula 12~~(VI) or (VII)~~ and a chemotherapeutic agent:



12



(VI)



(VII)

~~wherein~~

~~R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or~~

~~R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



~~, or~~

~~R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



;

~~W is R_1;~~

~~R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,~~

~~R_4 is hydrogen, alkyl or aryl, or~~

~~R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,~~

~~R_6 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$,~~

~~R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} where each R_{13} is independently hydrogen, alkyl or aryl,~~

~~R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,~~

~~the drawing "—" represents either a single bond or a double bond,~~

~~T is independently hydrogen, alkyl or aryl,~~

~~R_{14} and R_{15} are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or R_{14} and R_{15} are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,~~

~~and pharmaceutically acceptable salts thereof, and,~~

wherein the cancer is ovarian, pancreatic or prostate cancer, and

the chemotherapeutic agent is ~~platinum based or anti mitotic agent~~cisplatin, carboplatin, paclitaxel, gemcitabine or doxorubicin.

5.-7. (canceled).

8. (currently amended): A method of claim 4, wherein the administration of the compound of formula 12~~(VI) or (VII)~~ precedes the administration of the chemotherapeutic agent.

9. (currently amended): A method of claim 4, wherein the administration of the compound of formula 12~~(VI) or (VII)~~ and the chemotherapeutic agent is simultaneous.

10. (currently amended): A method claim 4, wherein the combination therapy follows observed resistance by cancer cells or tumour to [[a]]the chemotherapeutic agent.

11.-22. (canceled).

23. (currently amended): A pharmaceutical composition comprising a compound of formula 12~~(VI) or (VII)~~ and a chemotherapeutic agent:



12



(VI)



(VII)

~~wherein~~

~~R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or~~

~~R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



~~, or~~

~~R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from~~



~~;~~

~~W is R_1;~~

~~R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,~~

~~R_4 is hydrogen, alkyl or aryl, or~~

~~R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,~~

~~R_6 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$;~~

~~R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} where each R_{13} is independently hydrogen, alkyl or aryl,~~

~~R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,~~

~~the drawing "—" represents either a single bond or a double bond,~~

~~T is independently hydrogen, alkyl or aryl,~~

~~R_{14}, and R_{15} are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or R_{14} and R_{15} are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,~~

~~and pharmaceutically acceptable salts thereof, and,~~

wherein the chemotherapeutic agent is ~~platinum-based or anti-mitotic agent~~cisplatin, carboplatin, paclitaxel, gemcitabine or doxorubicins.

24.-28. (Canceled).